Is IMDX or NNNN more undervalued in 2026?

CirclFi compares Insight Molecular Diagnostics I (IMDX) and Anbio Biotechnology (NNNN) using 13 institutional-grade valuation models. IMDX has a Quality of Company score of 5.3/10 while NNNN scores 2.0/10.

Which is a better buy — IMDX or NNNN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMDX and NNNN valuations compare?

IMDX at $6.21 and NNNN at $34.41 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMDX vs NNNN Valuation Comparison 2026 — Intrinsic Value Analysis

IMDX

In Vitro & In Vivo Diagnostic Substances

Insight Molecular Diagnostics I

Quality

5.3

out of 10

Value Trap

SAFE

Price

$6.21

Last close

Models

10/13

Active

NNNN

In Vitro & In Vivo Diagnostic Substances

Anbio Biotechnology

Quality

2.0

out of 10

Value Trap

SAFE

Price

$34.41

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	IMDX Fair Value	IMDX Upside	NNNN Fair Value	NNNN Upside
Bayesian DCF	Intrinsic	$2.00	-67.9%	$6.12	-82.2%
Earnings Power Value	Intrinsic	$1.19	-71.6%	$1.40	-95.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMDX vs NNNN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMDX vs NNNN — Which Stock Is More Undervalued?

IMDX scores higher with a 5.3/10 quality rating vs NNNN's 2.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Insight Molecular Diagnostics I (IMDX) and Anbio Biotechnology (NNNN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMDX currently trades at $6.21 with a QOC of 5.3/10, while NNNN trades at $34.41 with a QOC of 2.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).